Immunology Trials

What is the long-term safety and efficacy of satralizumab in patients with NMOSD who completed the pivotal SAkuraSky and SAkuraStar phase 3 trials?

In adults with AQP4-IgG-positive neuromyelitis optica spectrum disorder, does ravulizumab (a long-acting terminal complement C5 inhibitor) reduce the risk of relapse compared with external placebo control from the PREVENT trial?

When is it safe to stop immunotherapy in MOGAD, and who relapses after discontinuation?

Treatment Discontinuation in MOGAD

How do complement inhibitors, anti-CD20, and other DMTs compare in preventing NMOSD relapses in the real world?

Comparative Efficacy of DMT in NMOSD

Does ponesimod 20 mg maintain its safety and efficacy in relapsing MS over 5 years of extended treatment?

Does a single intrathecal injection of autologous bone marrow-derived mesenchymal stem cells produce neuroregenerative effects in progressive multiple sclerosis?

Does high-dose vitamin D monotherapy reduce disease activity in patients with clinically isolated syndrome typical for multiple sclerosis?

Is tolebrutinib, a brain-penetrant BTK inhibitor, superior to teriflunomide in reducing annualized relapse rates and preventing disability worsening in patients with relapsing multiple sclerosis?

Does tolebrutinib, an oral brain-penetrant BTK inhibitor, slow disability progression in patients with nonrelapsing secondary progressive multiple sclerosis?